antibody

MSD to Buy B-Cell Depletion Therapy from Curon

Major US drugmaker MSD is to pay up to $1.3 billion to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, from biotechnology company Curon Biopharmaceutical.

CMC Biologics Hikes Capacity in Denmark

Shire Takes Novimmune’s Blood Therapy Rights

Merck Takes Antibody License from Teijin

MRC Licenses Hepatitis C Antibody to China

Mundipharma to Launch Biosimilar Truxima in Europe

Merck Settles Keytruda Patent Disputes

MedImmune and Abpro Spin Out Antibody Firm

Topics • Strategy

Leaving the Patent Cliff Behind

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

API Manufacturing

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

JMP Statistical Discovery / SAS Institute GmbH

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Dow Chemical Company

Anchored in Sustainability

Leading Transformation

Nova-Institut GmbH

Advanced Recycling Conference 2025: New Paths to the Circular Economy

Brenntag Downsizes Management Board, Retains Both Divisions

Concept Heidelberg

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance

Easyfairs Deutschland GmbH

Leading the way. Driving results.

CHEManager c/o Wiley-VCH Verlag

Upcoming Virtual Events

Interview

Driving Sustainability Through Collaboration

Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

EvaluatePharma